Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.Nutrients · 2024Trial
- SynbioticNutrients · 2024Trial
- Amino Acid-Fatty Acid Profile as a Novel Predictive Method in the Assessment of Diagnosis and Treatment Efficacy of Anxiety-Related Disorders and Mood Disorders.International journal of molecular sciences · 2026Review
- From Plate to Mind: Scientific Perspectives on Foods That May Influence Anxiety and Depression.Nutrients · 2026Review
- Eicosapentaenoic acid in emotional well-being and brain aging: evidence boundaries, clinical heterogeneity, and a peripheral-to-central resolution-biology framework.Frontiers in nutrition · 2026Review
- The dietary ligands, omega-3 fatty acid endocannabinoids and short-chain fatty acids prevent cytokine-induced reduction of human hippocampal neurogenesis and alter the expression of genes involved in neuroinflammation and neuroplasticity.Molecular psychiatry · 2025Article
- Vitamin A5: Evidence, Definitions, Gaps, and Future Directions.Nutrients · 2025Review
- The Role of Resolvin D1 in Indicating Chronic Inflammation and Axonal Damage in Bipolar Disorder: A Comparative Study of Manic and Depressive Episodes.Noro psikiyatri arsivi · 2025Article
- Omega-3 Polyunsaturated Fatty Acids and Blood-Brain Barrier Integrity in Major Depressive Disorder: Restoring Balance for Neuroinflammation and Neuroprotection.The Yale journal of biology and medicine · 2024Review
- Review
- Omega-3 Polyunsaturated Fatty Acids in Depression.International journal of molecular sciences · 2024Review
- The role of polyunsaturated fatty acids in the neurobiology of major depressive disorder and suicide risk.Molecular psychiatry · 2024Review
- The missing hallmark of health: psychosocial adaptation.Cell stress · 2024Article
- Personalized Medicine of Omega-3 Fatty Acids in Depression Treatment in Obese and Metabolically Dysregulated Patients.Journal of personalized medicine · 2023Review
- Resolvins and cysteinyl-containing pro-resolving mediators activate resolution of infectious inflammation and tissue regeneration.Prostaglandins & other lipid mediators · 2023Review
- Lipids in major depressive disorder: new kids on the block or old friends revisited?Frontiers in psychiatry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Chronic inflammation has been implicated in the pathophysiology of major depressive disorder (MDD). Activating the resolution of inflammation through ω-3 fatty acid supplementation may prove to be a successful therapeutic strategy for the treatment of MDD. Patients with MDD, body mass index >25 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.